

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09/857,994</u>	Prepared by <u>B2m</u>	Tracking Number <u>05927425</u>	
Examiner-GAUP <u>Padmanabhan - 1617</u>	Date <u>4-27-04</u>	Week Date <u>03/29/04</u>	
	No. of queries <u>1</u>	<u>IFW</u>	

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	<input checked="" type="checkbox"/> PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

- a. Page Missing
- b. Text Continuity
- c. Holes through Data
- d. Other Missing Text
- e. Illegible Text
- f. Duplicate Text
- g. Brief Description
- h. Sequence Listing
- i. Appendix
- j. Amendments
- k. Other

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text
- k. Other

MESSAGE PTO-1449: "Please either initial or line through citations." Copies attached, 16 pages.

Thank You,
Initials B2m

RESPONSE

initials

PHS/08A



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

<p>Application Number</p> <p>Filing Date</p> <p>Confirmation Number</p> <p>First Named Inventor</p> <p>Group Art Unit</p> <p>Examiner Name</p>			<p>09/857,994</p> <p>October 5, 2001</p> <p>4028</p> <p>John P. McKearn et al.</p> <p>1617</p> <p>San-ming R. Hui</p>					
			<p>Sheet 1 of 2</p>			<p>Attorney Docket No. PHA 2005 (3167/6Z/US)</p>		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	282.	6,077,850		Carter et al.	06-20-2000
	283.	6,087,392		Reiter	07-11-2000
	284.	6,110,984		Robinson	08-29-2000
	285.	6,114,361		Robinson et al.	09-05-2000
	286.	6,156,798		Reiter	12-05-2000
	287.	6,214,870	B1	McClure et al.	04-10-2001
	288.	6,277,878	B1	Nakao et al.	08-21-2001
	289.	6,294,558	B1	Ando et al.	09-25-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office	Number ⁴	Kind Code ² (if known)			
	290.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
	291.	EP	1 088 650	A1	Pfizer Products Inc.	04-04-2001	
	292.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Ind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/857,994
				Filing Date	October 5, 2001
				Confirmation Number	4028
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1617
				Examiner Name	San-ming R. Hui
Sheet	2	of	2	Attorney Docket No.	PHA 2005 (3167/6Z/US)

	293.	EP	1 104 760	A1	Pfizer Products Inc.	06-08-2001	
	294.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
	295.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
	296.	WO	97/48685	A1	Glaxo Group Limited	12-24-1997	
	297.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
	298.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
	299.	WO	98/47690	A1	G.D. Searle & Co.	10-29-1998	
	300.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
	301.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
	302.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
	303.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
	304.	WO	01/40216	A1	Pfizer Products Inc.	08-07-2001	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete If Known Application Number 09/857,994 Filing Date October 5, 2001 Confirmation Number Unknown First Named Inventor John P. McKearn et al. Group Art Unit 1646 Examiner Name Unknown	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				
Sheet	1	of	13	Attorney Docket No. PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 2 2003
 TECH CENTER 1601/200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1.	4,100,274		Dutta et al.	07-11-1978
	2.	4,105,681		Bollag et al.	08-08-1978
	3.	4,140,707		Cleare et al.	02-20-1979
	4.	4,215,215		Bollag et al.	07-29-1980
	5.	4,310,666		Zee-Cheng et al.	01-12-1982
	6.	4,472,382		Labrie et al.	09-18-1984
	7.	4,596,797		Schweikert et al.	08-24-1986
	8.	6,260,683		Holton et al.	10-05-1993
	9.	5,254,703		Holton	10-19-1993
	10.	5,272,171		Ueda et al.	12-21-1993
	11.	5,319,112		Kingston et al.	08-07-1994
	12.	5,344,991		Reitz et al.	09-06-1994
	13.	5,455,270		Kaplan et al.	10-03-1995
	14.	5,633,016		Johnson	05-27-1997
	15.	5,686,419		Powers et al.	11-11-1997
	16.	5,698,131		Baguley et al.	12-09-1997

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/857,994	
			Filing Date	October 5, 2001	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKearn et al.	
			Group Art Unit	1646	
			Examiner Name	Unknown	
Sheet	1	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 3 2003
 TECH CENTER/604/200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1.	4,100,274		Dutta et al.	07-11-1978
	2.	4,105,681		Bollag et al.	08-08-1978
	3.	4,140,707		Cleare et al.	02-20-1979
	4.	4,215,215		Bollag et al.	07-29-1980
	5.	4,310,666		Zee-Cheng et al.	01-12-1982
	6.	4,472,382		Labrie et al.	09-18-1984
	7.	4,596,797		Schweikert et al.	08-24-1986
	8.	5,250,683		Holton et al.	10-05-1993
	9.	5,254,703		Holton	10-19-1993
	10.	5,272,171		Ueda et al.	12-21-1993
	11.	5,319,112		Kingston et al.	08-07-1994
	12.	5,344,991		Reitz et al.	09-06-1994
	13.	5,455,270		Kaplan et al.	10-03-1995
	14.	5,633,016		Johnson	05-27-1997
	15.	5,688,419		Powers et al.	11-11-1997
	16.	5,696,131		Baguley et al.	12-09-1997

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/857,994
		Filing Date	October 5, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	1646
		Examiner Name	Unknown
Sheet 2 of 13	Attorney Docket No.	PHA 4295 (3167/6Z)	

17.	5,733,909	Black et al.	03-31-1998
18.	5,787,142	LaVole et al.	06-18-1998
19.	5,824,699	Kreft et al.	10-20-1998
20.	5,837,696	Golub et al.	11-17-1998
21.	5,869,524	Faill	02-09-1999
22.	5,952,381	Chen et al.	09-14-1999

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office	Number ⁴	Kind Code ² (if known)			
	23.	DE	195 48 798	A1	Dr. Karl Thomae GmbH	07-03-1997	A
	24.	DE	196 13 933	A1	Merck Patent GmbH	10-09-1997	A
	25.	DE	198 28 701	A1	Hoechst AG	01-08-1998	A
	26.	EP	0 010 458	A1	ANVAR	04-30-1980	A
	27.	EP	0 054 168	A1	Klinge Pharma GmbH & Co.	08-23-1982	A
	28.	EP	0 095 875	A2	Farmos Group Ltd.	12-07-1983	
	29.	EP	0 165 804	A2	Ciba-Geigy AG	12-27-1985	A
	30.	EP	0 198 836	A1	C.I.R.D.	10-29-1986	A
	31.	EP	0 236 940	B1	Ciba-Geigy AG	09-16-1987	
	32.	EP	0 260 744	B1	Janssen Pharmaceutica N.V.	03-23-1988	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Complete If Known	
		Application Number	09/857,994
		Filing Date	October 5, 2003
		Confirmation Number	Unknown
		First Named Inventor	John P. McKeam et al.
		Group Art Unit	1646
		Examiner Name	Unknown
Sheet 3	of 13	Attorney Docket No.	PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 3 2003
 TECH CENTER 1600 2003

33.	EP	0 299 402	A2	ASTA Pharma Aktiengesellschaft	01-18-1989	A
34.	EP	0 331 983	A2	F. Hoffmann-La Roche AG	09-13-1989	A
35.	EP	0 402 232	A1	Rhone-Poulenc Sante	12-12-1990	A
36.	EP	0 532 156	A1	Matsuno et al.	03-17-1993	
37.	EP	0 579 915	A1	F. Hoffmann-La Roche AG	01-26-1994	A
38.	EP	0 702 962	A2	Eli Lilly and Company	03-27-1996	
39.	EP	0 703 239	A1	Hoechst Aktiengesellschaft	03-27-1996	A
40.	EP	0 716 086	A1	Boehringer Mannheim GMBH	06-12-1996	
41.	EP	0 743 070	A2	Tatka Mudr et al.	11-20-1996	A
42.	EP	0 758 649	A1	Kureha Chemical Industry Co., Ltd.	02-19-1997	
43.	EP	0 882 734	A2	F. Hoffman-La Roche AG	12-09-1998	
44.	EP	0 921 119	A1	ADIR Et Compagnie	06-09-1999	A
45.	GB	2 282 598	A	Merck & Co., Inc.	04-12-1995	
46.	WO	87/07609	A1	Taiho Pharmaceutical Co., Ltd.	12-17-1987	A
47.	WO	93/11145	A1	Banyu Pharmaceutical Co., Ltd.	06-10-1993	
48.	WO	93/18652	A1	Merck & Co.	09-30-1993	
49.	WO	93/20229	A1	Genentech, Inc.	10-14-1993	
50.	WO	94/02466	A1	The Du Pont Merck Pharmaceutical Company	02-03-1994	
51.	WO	94/12169	A1	Merck & Co., Inc.	06-09-1994	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKeam et al.
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket No.	PHA 4295 (3167/6Z)

Sheet **4** of **13**

52.	WO	94/13635	A1	Merck Frosst Canada Inc.	08-23-1994
53.	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994
54.	WO	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994
55.	WO	94/25431	A1	The Wellcome Foundation Limited	11-10-1994
56.	WO	94/25468	A1	Glaxo, Inc.	11-10-1994
57.	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
58.	WO	94/27980	A1	G.D. Searle & Co.	12-08-1994
59.	WO	95/02603	A2	Pharmacia S.P.A.	01-26-1995
60.	WO	95/08327	A1	The Government of the United States of America	03-30-1995
61.	WO	95/11883	A1	G.D. Searle & Co.	05-04-1995
62.	WO	95/12606	A1	The Wellcome Foundation Limited	05-11-1995
63.	WO	95/15318	A1	G.D. Searle & Co.	08-08-1995
64.	WO	95/24199	A2	Cell Therapeutics, Inc.	09-14-1995
65.	WO	95/28426	A2	La Jolla Cancer Research Foundation	10-26-1995
66.	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
67.	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
68.	WO	96/00574	A1	Smithkline Beecham Corporation	01-11-1996
69.	WO	96/00581	A1	Texas Biotechnology Corporation	01-11-1996
70.	WO	96/01653	A1	Board of Regents, The University of Texas System et al.	01-25-1996

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/857,994	
			Filing Date	October 5, 2001	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKeam et al.	
			Group Art Unit	1646	
			Examiner Name	Unknown	
Sheet	5	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)

	71.	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996	
	72.	WO	96/03392	A1	G.D. Searle & Co.	02-08-1996	
	73.	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996	
	74.	WO	98/14745	A1	The Regents of the University of California	05-23-1998	
	75.	WO	98/21667	A1	Merck Frosst Canada Inc.	07-18-1996	
	76.	WO	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996	
	77.	WO	96/35774	A2	The Children's Medical Center Corporation	11-14-1996	
	78.	WO	96/36335	A1	Pharmacia S.P.A.	11-21-1996	
	79.	WO	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996	
	80.	WO	96/36622	A1	Indena S.P.A.	11-21-1996	
	81.	WO	96/36823	A1	Merck Frosst Canada Inc.	11-21-1996	
	82.	WO	96/37489	A1	Merck Frosst Canada Inc.	11-28-1996	
	83.	WO	97/08145	A1	G.D. Searle & Co.	03-06-1997	
	84.	WO	97/11718	A1	The Victoria University of Manchester	04-03-1997	
	85.	WO	97/15666	A1	The Children's Medical Center Corporation	05-01-1997	
	86.	WO	97/15676	A2	Abbott Laboratories	05-01-1997	
	87.	WO	97/19954	A1	Asta Medica Aktiengesellschaft	06-05-1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete If Known

Application Number	09/857,994
Filing Date	October 5, 2000
Confirmation Number	Unknown
First Named Inventor	John P. McKearney et al.
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket No.	PHA 4295 (3167/6Z)

RECEIVED
AUG 2 2 2003
TECH CENTER 160000000

Sheet 6 of 13


88.	WO	97/20835	A1	Harbor Branch Oceanographic Institution, Inc.	06-12-1997	
89.	WO	97/23451	A1	Merck Patent Gesellschaft Mit Beschränkter Haftung	07-03-1997	A
90.	WO	97/23480	A1	The Du Pont Merck Pharmaceutical Company	07-03-1997	
91.	WO	97/24116	A2	Allergan	07-10-1997	
92.	WO	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997	
93.	WO	97/31936	A2	Wisconsin Alumni Research Foundation	09-04-1997	
94.	WO	97/33887	A1	The Du Pont Merck Pharmaceutical Company	09-18-1997	
95.	WO	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997	
96.	WO	97/38497	A2	Mars, Incorporated	10-09-1997	
97.	WO	97/36860	A1	G.D. Searle & Co.	10-09-1997	
98.	WO	97/36863	A1	Merck Frost Canada Inc.	10-09-1997	
99.	WO	97/37658	A1	Boehringer Mannheim Italia S.P.A.	10-16-1997	
100.	WO	97/41844	A1	Alcon Laboratories, Inc.	11-13-1997	
101.	WO	97/47296	A2	Mount Sinai Hospital Corporation	12-18-1997	
102.	WO	97/49704	A1	Janssen Pharmaceutica N.V.	12-31-1997	
103.	WO	98/03484	A1	Merck Frost Canada Inc.	01-29-1998	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 		Complete if Known			
		Application Number	09/857,994		
		Filing Date	October 5, 2000		
		Confirmation Number	Unknown		
		First Named Inventor	John P. McKearney et al.		
		Group Art Unit	1646		
		Examiner Name	Unknown		
Sheet	7	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 2 2000
 TECH CENTER 1600-0830

	104.	WO	98/07432	A1	American Home Products Corporation	02-26-1998	
	105.	WO	98/07433	A1	Bristol-Myers Squibb Company	02-26-1998	
	106.	WO	98/12181	A1	Rutgers, The State University of New Jersey	03-28-1998	
	107.	WO	98/13350	A1	Zeneca Limited	04-02-1998	
	108.	WO	98/14188	A1	Ilax Oncology Inc.	04-09-1998	
	109.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998	
	110.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998	
	111.	WO	98/25603	A1	Ilax Oncology, Inc.	06-18-1998	
	112.	WO	98/25898	A1	G.D. Searle & Co.	06-18-1998	
	113.	WO	98/40104	A2	Yale University et al.	09-17-1998	
	114.	WO	98/45294	A1	Astra Pharmaceuticals Ltd.	10-15-1998	
	115.	WO	99/01131	A1	Smithkline Beecham Corporation	01-14-1999	
	116.	WO	99/05104	A1	Pfizer Pharmaceuticals Inc.	02-04-1999	
	117.	WO	99/10331	A1	Abbott Laboratories	03-04-1999	
	118.	WO	99/12930	A1	Glaxo Group Limited	03-18-1999	
	119.	WO	99/14194	A1	Merck Frost Canada Inc.	03-25-1999	
	120.	WO	99/14205	A1	Almirall Prodesfarma S.A.	03-25-1999	
	121.	WO	99/21583	A1	Warner-Lambert Company	05-08-1999	
	122.	WO	99/23087	A1	Merck Frost Canada & Co.	05-14-1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/857,994
		Filing Date	October 5, 2003
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearney et al.
		Group Art Unit	1646
		Examiner Name	Unknown
Sheet 8 of 13	Attorney Docket No.	PHA 4295 (3167/6Z)	

RECEIVED
 AUG 20 2003
 TECH CENTER 1600-2900

123.	WO	99/31067	A1	Rutgers, The State University of New Jersey	06-24-1999
124.	WO	99/41241	A1	Rutgers, The State University of New Jersey	08-19-1999

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
	125.	BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumour, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1)	
	126.	BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD	
	127.	BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- α in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569	
	128.	BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- α in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11	
	129.	BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79	
	130.	CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46	
	131.	DONG, Z. et al., Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88	
	132.	DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/857,994
		Filing Date	October 5, 2000
		Confirmation Number	Unknown
		First Named Inventor	John P. McKeown et al.
		Group Art Unit	1646
		Examiner Name	Unknown
Sheet 9 of 13	Attorney Docket No.	PHA 4295 (3167/6Z)	

133.	DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41
134.	FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16
135.	FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3
136.	FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39
137.	GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54
138.	GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6
139.	GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from Interferon α , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1188-1205, Vol. 91
140.	HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers
141.	IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54
142.	International Search Report for Application No. PCT/US99/30670, dated September 5, 2000
143.	JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3)
144.	JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-238, Vol.11



Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WFO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Ind of document by the appropriate symbols as indicated on the document under WFO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	09/857,994	
			Filing Date	October 5, 2000	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKearn et al.	
			Group Art Unit	1646	
			Examiner Name	Unknown	
Sheet	10	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)



145.	KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3	
146.	LINGEN, M.W., et al., Retinoic Acid and Interferon α Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58	
147.	LODE, H.N., et al., Synergy between an antiangiogenic Integrin α , antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA, Feb. 1999, pp. 1591-1596, Vol. 96	
148.	LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
149.	MACKEAN, M.J., et al., A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12)	
150.	MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247	
151.	MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J.Invest.Dermatol., April 1997, Abstract 202, Vol. 108, No. 4	
152.	MONTGOMERY, A.M.P., et al., Integrin $\alpha\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8858-8860, Vol. 91	
153.	MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1348, Vol. 39	
154.	MÖLLER, H., Antio-genesis-Inhibition and Intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8	
155.	NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/857,994	
			Filing Date	October 5, 2000	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKearn	
			Group Art Unit	1646	
			Examiner Name	Unknown	
Sheet	11	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)



RECEIVED
 AUG 2 2000
 TECH CENTER 1600-200

156.	NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39	
157.	O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88	
158.	OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxorubicin and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 58	
159.	PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by α IIb β 3, α V β 3, and α 5 β 1 Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32	
160.	POWLES, T.J., II.1 Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain	
161.	RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8	
162.	ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 988-975, Vol. 17, No. 3	
163.	RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7	
164.	SCHACHTER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3	
165.	SEFTOR, R.E.B., et al., Role of the α β 3 integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 19 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket No.	PHA 4295 (3167/6Z)

12

of

13

RECEIVED
AUG 20 2003
TECH CENTER 15012589

166.	SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, <i>Annals of the New York Academy of Science</i> , June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
167.	SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers	
168.	SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, <i>Blood</i> , 1998, pp. 240b, Vol. 92, No. 10	
169.	STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- α , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, <i>Journal of Clinical Oncology</i> , May 1998, pp.1820-1825, Vol. 16, No. 5	
170.	STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, <i>Journal of Clinical Oncology</i> , May, 1992, pp. 829-838, Vol. 10, No. 5	
171.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages ¹ , <i>Cancer Research</i> , Feb. 15, 1998, pp. 717-723, Vol. 58	
172.	TAKADA, Y., et al., Structures and functions of integrins, <i>Jikken Igaku</i> , 1998, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3	A
173.	TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, <i>Breast Cancer Research and Treatment</i> , 1995, pp. 227-236, Vol. 38	
174.	TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, <i>European Journal of Cancer</i> , 1996, pp. 2481-2486, Vol. 32A, No. 14	
175.	THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, <i>Blood</i> , 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 			Complete If Known		
			Application Number	09/857,994	
			Filing Date	October 5, 2001	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKeam et al.	
			Group Art Unit	1646	
			Examiner Name	Unknown	
Sheet	13	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)

RECEIVED
 AUG 2 2003
 TECH CENTER 1600/2900

	176.	TOLMA, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122	
	177.	TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7	
	178.	TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1	
	179.	VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha v \beta 3$, Impl. Adv. Onc., 1996, pp. 69-87	
	180.	ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
	181.	ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450